Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Oncologist

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/THEONCOLOGIST.2016-0055PMID 27401894PMCID PMC5061539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cited by this paper
• Non-small Cell Lung Cancer

  2016cited by this paper
• Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.

  2015cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2015cited by this paper
• Nivolumab in NSCLC: latest evidence and clinical potential

  2015cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper

• Incidence of Reported Pseudoprogression on 18F‐FDG PET/CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy

  2026cites this paper
• Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review.

  2026cites this paper
• Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis

  2025cites this paper
• Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects

  2025cites this paper
• Cervical cancer treatment and nursing considerations: Best practices for effective care.

  2025cites this paper
• Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study

  2024cites this paper
• Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors

  2024cites this paper
• Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo

  2024cites this paper
• Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

  2024cites this paper
• Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review

  2024cites this paper
• Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity

  2024cites this paper
• A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database

  2024cites this paper
• From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases

  2024cites this paper
• Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist.

  2024cites this paper
• Research Progress of Penpulimabin Antitumor Therapy

  2024cites this paper
• Neoadjuvant Immunotherapy as a risk factor for hashimoto’s disease

  2024cites this paper
• The Roles of T cells in Immune Checkpoint Inhibitor-Induced Arthritis

  2024cites this paper
• Complications of immuno‐oncology care: what urologist should know

  2024cites this paper
• Uncontrolled inhibition of checkpoints

  2024cites this paper
• Psoríase de novo ou exacerbação por inibidores de checkpoint PD‐1

  2024cites this paper
• Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management

  2023cites this paper
• Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.

  2023cites this paper
• Pembrolizumab-Induced Hypothyroidism: A Case Report

  2023cites this paper
• Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies

  2023cites this paper
• Immune Checkpoint Inhibitors as A Threat to Reproductive Function: A Systematic Review.

  2023cites this paper
• Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

  2023cites this paper
• Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

  2023cites this paper
• Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience

  2023cites this paper
• Thromboembolism Adverse Events Caused by Immune Checkpoint Inhibitor Therapy: A Disproportionality Study from 2010 to 2020 based on FAERS Database

  2022cites this paper
• A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial

  2022cites this paper
• Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study

  2022cites this paper
• Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer

  2022cites this paper
• Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival

  2022cites this paper
• Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation

  2022cites this paper
• Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab

  2022cites this paper
• Immunotherapy-Associated Hypophysitis Under Anti-PD1: Two Case Reports.

  2022cites this paper
• Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases

  2022cites this paper
• PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review

  2022cites this paper
• Thyroid Dysfunction in Non‐Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta‐Analysis

  2022cites this paper
• Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study

  2022cites this paper
• The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy

  2022cites this paper
• Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors

  2022cites this paper
• Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma

  2022cites this paper
• Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1

  2022cites this paper
• TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy

  2021cites this paper
• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

  2021cites this paper
• Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.

  2021cites this paper
• Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy

  2021cites this paper
• Unusual severe gastritis and gastric ulcers caused by pembrolizumab

  2021cites this paper
• Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

  2021cites this paper
• The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response

  2021cites this paper
• Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.

  2021cites this paper
• Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

  2021cites this paper
• Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis

  2021cites this paper
• Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment

  2021cites this paper
• Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

  2021cites this paper
• Sarcoid-like reaction: a unique response to immunotherapy in malignant melanoma

  2021cites this paper
• Treatment Toxicity

  2021cites this paper
• Small and Large Intestine (I): Malabsorption of Nutrients

  2021cites this paper
• How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.

  2021cites this paper
• Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models

  2021cites this paper
• Checkpoint inhibitor–induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin’s lymphoma

  2021cites this paper
• Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels

  2021cites this paper
• Immune-mediated enteropathies: From bench to bedside.

  2021cites this paper
• Sarcoid-like reaction in cases treated by checkpoint inhibitors

  2021cites this paper
• Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma

  2021cites this paper
• Supportive Maßnahmen in der gynäkologischen Onkologie

  2021cites this paper
• Case with metastatic cutaneous malignant melanoma that developed Vogt–Koyanagi–Harada-like uveitis following pembrolizumab treatment

  2021cites this paper
• Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism

  2021cites this paper
• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

  2021cites this paper
• Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities

  2021cites this paper
• Infliximab-Induced Acute Liver Failure in a Patient With Crohn's Disease Requiring Orthotopic Liver Transplantation

  2021cites this paper
• The role of immunosuppressive agents in the management of severe and refractory immune‐related adverse events

  2020cites this paper
• S1-ROLE OF PATHOLOGIST IN MODERN ONCOLOGICAL TREATMENT

  2020cites this paper
• Reply to Y. Inagaki et al.

  2020cites this paper
• A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab

  2020cites this paper
• Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma

  2020cites this paper
• Überblick Nebenwirkungsmanagement moderner Immuntherapien

  2020cites this paper
• Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients

  2020cites this paper
• Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

  2020cites this paper
• Diabetes Mellitus and Glucose Metabolism TYPE 1 DIABETES MELLITUS Anti PD 1 Induced Type 1 Diabetes

  2020cites this paper
• Treatment of Cancer Pain

  2020cites this paper
• Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment

  2020cites this paper
• NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

  2020cites this paper
• Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy

  2020cites this paper
• Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.

  2020cites this paper
• Systemic Therapies for Advanced Basal Cell and Cutaneous Squamous Cell Carcinomas: Novel Targeted Therapies and Immunotherapies.

  2020cites this paper
• Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.

  2020cites this paper
• Steroid-responsive pancreatitides

  2020cites this paper
• Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.

  2020cites this paper
• Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy.

  2020cites this paper
• Management Of Immunotherapy Adverse Events In Oncological Patients: Anti-Ctla-4, Anti-Pd-1/Pd-L1.

  2020cites this paper
• A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma

  2020cites this paper
• The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases

  2020cites this paper
• Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction.

  2020cites this paper
• Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.

  2020cites this paper
• Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

  2020cites this paper
• Oncologic Emergencies: Immune-Based Cancer Therapies and Complications

  2020cites this paper
• Role of radiation therapy in brain metastases management.

  2020cites this paper
• Advances in immunotherapy for colorectal cancer: a review

  2020cites this paper